Small Cell Lung Cancer Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Small Cell Lung Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Small Cell Lung Cancer Pipeline Outlook Report
Key Takeaways from the Small Cell Lung Cancer Pipeline Report
In August 2025, AstraZeneca announced a Phase III study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy.
In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).
In August 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC.
DelveInsight's Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
The leading Small Cell Lung Cancer Companies such as Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others.
Promising Small Cell Lung Cancer Pipeline Therapies such as Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others.
Discover how the Small Cell Lung Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Small Cell Lung Cancer Clinical Trials and Studies
Small Cell Lung Cancer Emerging Drugs Profile
AMG 757: Amgen
AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.
APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.
The Small Cell Lung Cancer Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Cell Lung Cancer Treatment.
Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Cell Lung Cancer market.
Get a detailed analysis of the latest innovations in the Small Cell Lung Cancer Pipeline. Explore DelveInsight's expert-driven report today! @ Small Cell Lung Cancer Unmet Needs
Small Cell Lung Cancer Companies
Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others.
Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type
Small Cell Lung Cancer Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Small Cell Lung Cancer Developments @ Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Small Cell Lung Cancer Pipeline Report
Coverage- Global
Small Cell Lung Cancer Companies- Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others.
Small Cell Lung Cancer Pipeline Therapies- Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others.
Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Small Cell Lung Cancer drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Small Cell Lung Cancer Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Small Cell Lung Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Small Cell Lung Cancer – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Small Cell Lung Cancer Collaboration Deals
Late Stage Products (Phase III)
Pembrolizumab: Merck & Co
Mid Stage Products (Phase II)
Dostarlimab: GlaxoSmithKline
Early Stage Products (Phase I)
AMG 757: Amgen
Preclinical/Discovery Stage Products
S 055746: Vernalis
Inactive Products
Small Cell Lung Cancer Key Companies
Small Cell Lung Cancer Key Products
Small Cell Lung Cancer- Unmet Needs
Small Cell Lung Cancer- Market Drivers and Barriers
Small Cell Lung Cancer- Future Perspectives and Conclusion
Small Cell Lung Cancer Analyst Views
Small Cell Lung Cancer Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/small-cell-lung-cancer-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 hours ago
- Globe and Mail
Small Cell Lung Cancer Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Small Cell Lung Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Small Cell Lung Cancer Pipeline Outlook Report Key Takeaways from the Small Cell Lung Cancer Pipeline Report In August 2025, AstraZeneca announced a Phase III study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy. In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS). In August 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC. DelveInsight's Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment. The leading Small Cell Lung Cancer Companies such as Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others. Promising Small Cell Lung Cancer Pipeline Therapies such as Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others. Discover how the Small Cell Lung Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Small Cell Lung Cancer Clinical Trials and Studies Small Cell Lung Cancer Emerging Drugs Profile AMG 757: Amgen AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer. APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC. The Small Cell Lung Cancer Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Small Cell Lung Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Cell Lung Cancer Treatment. Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Cell Lung Cancer market. Get a detailed analysis of the latest innovations in the Small Cell Lung Cancer Pipeline. Explore DelveInsight's expert-driven report today! @ Small Cell Lung Cancer Unmet Needs Small Cell Lung Cancer Companies Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others. Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravitreal Subretinal Topical Molecule Type Small Cell Lung Cancer Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Small Cell Lung Cancer Developments @ Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Small Cell Lung Cancer Pipeline Report Coverage- Global Small Cell Lung Cancer Companies- Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others. Small Cell Lung Cancer Pipeline Therapies- Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others. Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Small Cell Lung Cancer drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Small Cell Lung Cancer Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Small Cell Lung Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Small Cell Lung Cancer – DelveInsight's Analytical Perspective In-depth Commercial Assessment Small Cell Lung Cancer Collaboration Deals Late Stage Products (Phase III) Pembrolizumab: Merck & Co Mid Stage Products (Phase II) Dostarlimab: GlaxoSmithKline Early Stage Products (Phase I) AMG 757: Amgen Preclinical/Discovery Stage Products S 055746: Vernalis Inactive Products Small Cell Lung Cancer Key Companies Small Cell Lung Cancer Key Products Small Cell Lung Cancer- Unmet Needs Small Cell Lung Cancer- Market Drivers and Barriers Small Cell Lung Cancer- Future Perspectives and Conclusion Small Cell Lung Cancer Analyst Views Small Cell Lung Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
9 hours ago
- Globe and Mail
The Smartest Dividend Stocks to Buy With $10,000 Right Now
Key Points Several strategic decisions United Parcel Service has made of late are starting to come together just as the world shakes off the last of the post-pandemic delivery and logistics lull. Shares of drugmaker Pfizer have been upended by price-control worries and a wind-down of its booming COVID-19 business. But there's reason to look for better days on the horizon. Defense contractor Lockheed Martin looks and seems vulnerable. The market's not seeing its future in quite the right light, though. 10 stocks we like better than Lockheed Martin › Are you looking to put a sizable chunk of cash to work generating investment income? Whether you intend to live on this income or reinvest it to bolster your portfolio's overall growth, there are several great dividend-paying options out there right now. Here's a closer look at three of your best bets at this time, not despite each stock's recent turbulence and mostly bearish drama but because of it. United Parcel Service You probably already know that United Parcel Service 's (NYSE: UPS) revenue dwindled after soaring during and because of the COVID-19 pandemic, taking a similar toll on the bottom line. Indeed, the delivery giant's business has been stagnant -- at best -- since 2022. Its second-quarter sales and income both fell on the order of 1% year over year, extending its anemic results in the meantime. The amount of business and pricing power that was in place just four years ago simply isn't there anymore. UPS stock's 63% pullback from its 2022 peak to yet another new multiyear low reached earlier this month, however, is overdone at the exact wrong time to price in such pessimism. Not every investor will immediately agree with this assessment. The threat of a lingering tariff war continues to threaten United Parcel Service's business following its post-pandemic slowdown. The company isn't exactly helping its stock either, opting not to offer any guidance with its recently released Q2 report, after which CEO Carol Tomé lamented during the quarterly earnings call that "for our sector, this remains a very unsettling time." There's an argument to be made, however, that all the worst-case scenario is now priced in at a time when things are on the verge of turning around. The decision to make fewer but more profitable deliveries has already been enacted, for instance. And the company has already cut $3.5 billion worth of annual overhead, with total yearly savings of $6 billion being targeted further down the road. It's just going to take a little more time to make and see the adjustment to such changes. The backdrop is still quite bullish in the meantime, though. An outlook from Mordor Intelligence suggests the global parcel delivery market is set to grow at an average annual pace of just over 5% through 2030, jibing with expectations from Global Market Insights. That's better growth than we've seen at any point since the wind-down of the coronavirus contagion. Newcomers will not only be plugging into UPS while its forward-looking yield stands at 7.4%, but while the stock's priced dirt cheap -- at only 13 times this year's analyst-expected per-share earnings of $6.64. It's not going to get much cheaper than that. Pfizer It's a tough time to be excited about owning any pharmaceutical stocks, but especially Pfizer (NYSE: PFE). Not only is the federal government looking to force drugmakers to offer better prices to its Medicare program, but Pfizer still hasn't restored the revenue it lost once the need for its COVID-19 vaccine and treatment evaporated in 2023. That's the chief reason shares have been more than halved since late 2021. Well, that and the fact that the company is technically dishing out more in dividends than it's earning while it's facing a handful of patent expirations in the foreseeable future. Just don't lose perspective here. On any of it. Take its underfunded dividend as an example. It's not actually underfunded. Last year's reported per-share earnings of $1.41 were less than the full-year dividend payout of $1.68 per share, but that figure reflected a one-time accounting charge. Stripping this expense out of the equation reinflates earnings to a more normalized figure of $3.11 per share, easily covering its dividend. Pfizer also has replacements in the works for all its COVID drugs that are less needed, as well as its drugs with patents set to expire in the foreseeable future. Vepdegestrant (for ER+/HER2- metastatic breast cancer) and sigvotatug vedotin (for metastatic non-small cell lung cancer) are both in late-stage trials now, for instance, as part of a developmental pipeline that consists of around 50 oncology drugs. Although none of these drugs are going to be approved and marketed in the immediate future, the company is aiming to launch at least eight new cancer drugs by 2030. The market could begin rewarding their eventual success much sooner, though. The company's also looking to enter the multibillion-dollar weight-loss market with its own GLP-1 receptor agonist, which is based on the same basic science as well-known semaglutide. And as for the threat of lower drug prices for Medicare-covered patients, don't read too much into it. This threat remains in permanent circulation and rarely causes as much trouble as feared. As BMO Capital Markets analyst Evan David Seigerman noted back in May, when President Donald Trump first ramped up his rhetoric on the matter, his plan "could be more rhetoric than actual implementable policy." In other words, it's more bark than bite. Don't be surprised to see Pfizer shares start climbing again once more investors start connecting all these dots, particularly given how their weakness has inflated the stock's forward-looking dividend yield to 7.2%. Lockheed Martin Finally, add defense contractor Lockheed Martin (NYSE: LMT) to your list of dividend stocks to buy with bigger amounts of capital while its forward-looking dividend yield is a respectable 3.1%. It's yet another victim of federal budget real and feared. In June, for instance, the U.S. Department of Defense halved its previous order of F-35 fighter jets (which account for more than one-fourth of Lockheed's annual revenue) for the government's fiscal year beginning in October. That followed March's news that the DoD chose Boeing rather than Lockheed to manufacture the next-generation F-47 fighter plane... a contract that could have been worth hundreds of billions of dollars over the course of many, many years. Meanwhile, support for Ukraine in its conflict against Russia appears to be waning, potentially crimping deliveries of new weaponry to the region. All told, Lockheed Martin shares are down more than 30% from October's peak and still testing new 52-week lows on these worries. . Once again, though, don't lose perspective. The U.S. military may not need as many F-35 fighter planes as it thought it would in the year ahead, nor does it want Lockheed-Martin to manufacture its next generation of fighter jets. It still needs much of Lockheed's weapons and military hardware, though, like its newly unveiled artificial intelligence-powered synthetic aperture radar (SAR) that facilitates airborne maritime surveillance or its new magnetic anomaly detection technology (capable of finding submerged submarines) for its Sikorsky MH-60R "Seahawk" maritime helicopters. And just last month, the U.S. Missile Defense Agency added another $2 billion to an $8.3 billion contract with Lockheed to provide it with terminal high-altitude area defense (THAAD) interceptor missiles. Sure, investors would love to see strong and sustained demand for the F-35, which generates maintenance revenue long after the purchase of the aircraft is completed. Shareholders would have also been thrilled to see the company win the F-47 contract to the same reason. Lockheed Martin still has a range of ways to monetize its military hardware know-how for the long haul, though. Let's also not forget that one of the few things the United States' two major political parties agree on is the need to fully fund the nation's ability to defend itself and its interests. Even in the face of economic uncertainty, the U.S. Senate's overseeing panel recently approved a defense budget of $852 billion for the upcoming year, up just a bit from this year's figure and extending a multiyear growth trend that isn't apt to slow anytime soon. Admittedly, Lockheed stock's 3.1% yield isn't huge. It's based on a dividend; however, that's now been raised for 22 consecutive years. So close to becoming dividend royalty, it's unlikely the company's going to stop raising its annual dividend payments now. Should you invest $1,000 in Lockheed Martin right now? Before you buy stock in Lockheed Martin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Lockheed Martin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
11 hours ago
- Globe and Mail
Heidrick (HSII) Q2 Revenue Jumps 14%
Key Points Revenue grew 13.9% in Q2 2025, beating GAAP revenue expectations by $24.3 million. Adjusted EPS reached $0.85, exceeding analyst estimates by 15.4% (non-GAAP). On-Demand Talent and Heidrick Consulting achieved adjusted EBITDA profitability for the first time. These 10 stocks could mint the next wave of millionaires › Heidrick & Struggles International (NASDAQ:HSII), a global executive search and leadership advisory firm, reported quarterly earnings on August 4, 2025. The most notable news was its GAAP revenue of $317.2 million, which surpassed the consensus GAAP estimate of $292.9 million by $24.3 million. Adjusted earnings per share (EPS) were $0.85 (non-GAAP), beating the expected $0.74 (non-GAAP). The company delivered growth across all regions and segments, as well as new adjusted EBITDA profitability in its On-Demand Talent and consulting operations. Overall, the quarter reflected broad-based outperformance versus expectations, though management noted the presence of ongoing cost pressures and a cautious forward outlook due to uncertainties in the broader economic environment. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) $0.85 $0.74 $0.67 26.9 % Revenue (Non-GAAP) N/A N/A $278.6 million N/A Adjusted EBITDA $33.9 million $28.8 million 17.5 % Adjusted EBITDA Margin 10.7 % 10.3 % 0.4 pp Adjusted Net Income $18.1 million $14.1 million 28.4 % Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Business Overview and Strategic Focus Heidrick & Struggles International operates as a retained executive search and human capital advisory firm. It provides services like senior-level executive placements, interim talent solutions, and leadership consulting to corporate clients globally. The company is organized across three primary segments: Executive Search, On-Demand Talent, and Heidrick Consulting, with a strong worldwide presence. It serves its clients through a network of over 60 offices in 30 countries, working with large multinationals, private equity firms, and not-for-profits. The company's recent strategy has focused on driving growth outside its core executive search business. Acquisitions in both the On-Demand Talent area (notably Atreus Group) and consulting (such as businessfourzero) reflect a push into new, adjacent service lines. Key factors for success hinge on maintaining a differentiated competitive position in executive recruiting, scaling its new segments, and investing in technology platforms to improve client value and consultant productivity. Technological investment—like proprietary platforms for client engagement and assessment—remains an ongoing priority. Quarter Highlights and Segment Developments The Executive Search segment remained the largest contributor, generating $238.2 million in net revenue, up 13.4% from the prior year. All global regions saw growth, with Europe standing out at 30.9%, followed by Asia Pacific at 12.0% and the Americas at 8.9%. Consultant productivity improved to $2.3 million annualized, compared to $2.0 million in Q2 2024, and the number of search confirmations rose 5.2%. Revenue per search increased to $162,000 from $151,000. However, the adjusted EBITDA margin in this segment tightened from 25.1% in Q2 2024 to 22.9%. This margin compression was driven by salaries and benefits as a share of net revenue rising to 65.9%. For On-Demand Talent—a segment offering interim executives and project-based talent—the top-line (GAAP net revenue) grew 14.3% to $47.9 million. The segment reached positive adjusted EBITDA of $1.0 million, a marked turnaround from a $1.6 million loss in Q2 2024. The division has benefited from the integration of acquired businesses and increased client demand for flexible leadership solutions. Margin levels are still relatively low at 2.1% (adjusted EBITDA margin for On-Demand Talent), so efficiency and scale will be important areas to watch. Heidrick Consulting saw net revenue climb 16.6% to $31.2 million, with Adjusted EBITDA was $0.6 million, compared to a $1.4 million loss in Q2 2024. The segment's adjusted EBITDA margin improved to 1.8%. The business has been reshaped through targeted acquisitions and simplifying service lines, though management confirmed that margins remain well below longer-term group targets of 11–13%, as efficiency initiatives are still being rolled out. Operating cost trends were mixed. While general and administrative expenses (covering overheads like office and support costs) improved as a percentage of net revenue to 14.6% in Q1 2025, Salaries and benefits as a share of net revenue rose to 65.9% from 63.8% in Q2 2024, while operating margin improved to 8.0% from (1.5)% over the same period. Research and development spending was $6.0 million, or 1.9% of revenue, funding investments in proprietary tools like the Heidrick Leadership Framework and digital client platforms. Cash levels declined compared to the start of the year, from $515.6 million at December 31, 2024, to $211.2 million at June 30, 2025. This decline was due to investment in marketable securities and cash outflows for compensation. All segments and geographies posted revenue growth. The company's client list remained highly diversified, with no single client accounting for more than 2% of net revenue in 2024. External risks noted by management included ongoing macroeconomic uncertainty, rising interest rates, and foreign currency fluctuations. The company declared a quarterly dividend of $0.15 per share, in line with previous quarters. Outlook and Topics for the Coming Quarter For the third quarter, management guided to revenue between $295 million and $315 million. At the midpoint, this implies growth of about 9.5% compared to Q3 2024. Guidance was presented as measured, reflecting possible impacts from macroeconomic factors such as inflation, global conflicts, currency moves, and interest rates. The company did not issue explicit projections for earnings per share or adjusted EBITDA for the next period. As such, investors and followers should expect some caution about near-term demand and project timing in the coming months. Looking ahead, observers should focus on trends in margins, especially in Executive Search, where labor and incentive costs have been rising. The recently profitable On-Demand Talent and Consulting segments offer promising diversification, but their overall adjusted EBITDA margins (2.1% for On-Demand Talent and 1.8% for Consulting, non-GAAP) need to approach group targets for these businesses to become core contributors. As the company continues to balance organic investment, technology upgrades, and careful cost control, progress in operating efficiency and capital allocation will be important. The company declared a quarterly dividend of $0.15 per share, unchanged from the prior period. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
